Pfizer Inc. signed a multi-year agreement to make Gilead Sciences Inc.’s antiviral drug remdesivir in a bid to ramp up supply of the Covid-19 treatment.
As the world awaits a Covid-19 vaccine, the next big advance in battling the pandemic could come from a class of biotech therapies widely used against cancer and other disorders – antibodies designed specifically to attack this new virus.
New Membrane Uses Pressure to Help Solve Bioprocess Waste Problem Published: JulY 23, 2020 By Gail Dutton BioSpace A new membrane filtration method could solve the problem of the […]
Ohio-based startup Forge Biologics closed a $40 million Series A financing round that will be used to expand manufacturing capabilities and support the clinical development of a gene therapy program for rare diseases, including the typically fatal Krabbe disease.
Companies Face Challenge of Enrolling Patients in COVID-19 Vaccine Studies Published: July 6, 2020 By Mark Terry BioSpace As of June 29, there were 13 vaccines against COVID-19 in […]
The Coalition for Epidemic Preparedness Innovation (CEPI) plans to have two or three manufacturing plants for each vaccine, James Robinson, a longtime biopharma executive leading CEPI’S vast manufacturing push, said in an interview.
Gilead Sciences Inc. expects supply of the potential COVID-19 drug remdesivir to exceed two million courses by year-end, more than double the company’s previous target of 1 million.
Emergent BioSolutions signed an $87 million deal to make AstraZeneca’s experimental COVID-19 vaccine in the United States.
AstraZeneca announced plans to manufacture 2 billion doses of the University of Oxford’s COVID-19 vaccine, AZD122.
Maryland-based Novavax snagged $384 in additional grant funding to advance the company’s vaccine candidate against COVID-19.
